Navigation Links
Sanofi-aventis U.S. Announces Settlement of Medicaid 'Best Price' Investigation
Date:5/28/2009

BRIDGEWATER, N.J., May 28 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today a civil settlement with the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts to resolve a Medicaid "best price" investigation involving one of its predecessor companies, Aventis Pharmaceuticals Inc. (API).

The settlement ends an investigation into whether sales by API of certain products to a managed care organization for resale under that organization's private label should have been included in the "best price" calculations used to compute Medicaid rebates for API products. Although the company believes API acted in accordance with the law at the time, the company elected to resolve this legacy matter through this settlement, without admitting any wrongdoing.

The settlement calls for payment of $95.5 million (plus interest) which includes payment of approximately $55.5 million to resolve all federal claims and the establishment of an "opt-in" fund of approximately $40 million for states desiring to resolve Medicaid rebate claims relating to the same conduct. The total amount of the settlement is fully covered by existing reserves.

This settlement also provides for an Addendum to the five-year Corporate Integrity Agreement with the Office of the Inspector General of the Department of Health and Human Services that the company entered into in August 2007. The Addendum, which deals primarily with matters related to the Medicaid "best price" calculations, will run concurrently with the August 2007 agreement.

About sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

For more information, www.sanofi-aventis.us or www.sanofi-aventis.com

    Media Contact:
    Lisa Buffington
    908-981-6569
    Lisa.Buffington@sanofi-aventis.com


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... Nanowear on their recent FDA Class II 510(k) clearance for their flagship medical ... in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other ...
(Date:12/2/2016)... bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest ... members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited ... introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... 2016 Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... . The 15,200 square foot state-of-the-art facility officially opened ... brings the total number of BPC,s plasma collection centers ... BPC,s Chief Executive Officer said "We are pleased to ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):